SCHEMBL2301258

SCHEMBL2301258

CCC/C=[C]\C1CCCCC1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.33
ADH1A P07327 1/20 0.31
SHBG P04278 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2301260 1.00 CYP1A2 (0.33) CYP1A2ADH1ASHBG
SCHEMBL6033218 0.98 CYP1A2 (0.30) CYP1A2
SCHEMBL6593055 0.93
SCHEMBL6591028 0.88
SCHEMBL6956347 0.87 CYP1A2 (0.40) CYP1A2
SCHEMBL2303897 0.87 CYP1A2 (0.40) CYP1A2
SCHEMBL441908 0.81 SHBG (0.32) CYP1A2ADH1ASHBG
SCHEMBL2240665 0.78
SCHEMBL6591003 0.74
SCHEMBL962970 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4759762-B2 2011-08-31 JP claimed
EP-0891331-B1 N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY VERTEX PHARMA (US) 2003-10-01 EP claimed
EP-0891331-A1 N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY Vertex Pharmaceuticals Incorporated (US) 1999-01-20 EP claimed
US-5717092-A Compounds with improved multi-drug resistance activity VERTEX PHARMACEUTICALS INC. (US) 1998-02-10 US claimed
WO-1997036869-A1 N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-10-09 WO claimed
US-20240044876-A1 IDENTIFYING NEW THERAPEUTIC AGENTS WARP DRIVE BIO, INC. 2024-02-08 US disclosed
US-11644460-B2 Identifying new therapeutic agents Revolution Medicines, Inc. (US) 2023-05-09 US disclosed
US-10989710-B2 Identifying new therapeutic agents Revolution Medicines, Inc. (US) 2021-04-27 US disclosed
US-20190271691-A1 IDENTIFYING NEW THERAPEUTIC AGENTS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2019-09-05 US disclosed
US-10203323-B2 Identifying new therapeutic agents WARP DRIVE BIO, INC. (US) 2019-02-12 US disclosed
US-20160341719-A1 IDENTIFYING NEW THERAPEUTIC AGENTS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2016-11-24 US disclosed
US-9428845-B1 Identifying new therapeutic agents WARP DRIVE BIO, INC. (US) 2016-08-30 US disclosed
US-5935954-A TREATING THE PATIENT SUFFERING FROM PARKINSON'S DISEASE, ALZHIMER'S DISEASE, STROKE AND ISCHEMIA ASSOCIATED WITH STROKE, NEURAL PAROPATHY, SCIATIC CRUSH, SPINAL CORD INJURY OR FACIAL NERVE CRASH VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-08-10 US disclosed
EP-0930298-A1 FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1999-07-21 EP disclosed
EP-0916668-A1 CHEMOKINE RECEPTOR ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 1999-05-19 EP disclosed
EP-0891331-A1 N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY Vertex Pharmaceuticals Incorporated (US) 1999-01-20 EP disclosed
US-5750540-A SIDE EFFECT REDUCTION BANYU PHARMACEUTICAL CO., LTD. (JP) 1998-05-12 US disclosed
EP-0823423-A1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1998-02-11 EP disclosed
US-5717092-A Compounds with improved multi-drug resistance activity VERTEX PHARMACEUTICALS INC. (US) 1998-02-10 US disclosed
WO-1997036869-A1 N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-10-09 WO disclosed